Related Experiment Video
Updated: May 29, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
Leishmaniasis impact and treatment access
M den Boer1, D Argaw, J Jannin
1Leishmaniasis Control Programme, WHO/IDM. Av. Appia, Geneva, Switzerland.
Abstract:
According to disease burden estimates, leishmaniasis ranks third in disease burden in disability-adjusted life years caused by neglected tropical diseases and is the second cause of parasite-related deaths after malaria; but for a variety of reasons, it is not receiving the attention that would be justified seeing its importance. This is especially apparent in the unnecessarily and unacceptably poor access to timely and appropriate treatment for patients. To our knowledge, this is the first publication that addresses the major issues associated with poor access to drugs for leishmaniasis and that outlines a number of feasible and practical solutions.
More Related Videos
11:36Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
12:22A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
Published on: December 30, 2012
Related Concept Videos
Leishmaniasis
Antiprotozoal Agents
American Trypanosomiasis
Rocky Mountain Spotted Fever
Trichomoniasis
Toxoplasmosis